L-2',3'-dideoxy nucleoside analogs as anti-Hepatitis B (HBV) agents
AssigneeYale University
InventorsTai-Shun Lin, Yung-Chi Cheng
Life of this patent
Estimating the term…
Abstract
The present invention relates to the surprising discovery that certain dideoxynucleoside analogs which contain a dideoxy ribofuranosyl moiety having an L-configuration (as opposed to the naturally occurring D- configuration) exhibit unexpected activity against Hepatitis B virus (HBV). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of HBV, HIV and other retroviruses, most preferably HBV.
Claims3
The compound 1-(2,3-Dideoxy-beta-L-ribofuranosyl)-5-fluorocytosine.
A pharmaceutical composition comprising a therapeutically effective amount of the compound 1-(2,3-Dideoxy-beta-L-ribofuranosyl)-5-fluorocytosine in combination with a pharmaceutically acceptable additive, carrier or excipient.
A method of treating an HBV infection in a patient comprising administering to said patient a therapeutically effective amount of the compound 1-(2,3-Dideoxy-beta-L-ribofuranosyl)-5-fluorocytosine.
Dependencies are inferred from the claim text.